-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
News from March 25, 2021 //---Previous studies have shown that some patients with melanoma respond well to immunotherapy.
According to a recent study, a small percentage of these patients will also develop autoimmunity against their normal melanocytes (cells that cause melanoma), a phenomenon called vitiligo.
For a long time, melanoma survivors with vitiligo have been considered as a special population with a good prognosis and a strong immune system (T cell) response.
According to a recent study, a small percentage of these patients will also develop autoimmunity against their normal melanocytes (cells that cause melanoma), a phenomenon called vitiligo.
For a long time, melanoma survivors with vitiligo have been considered as a special population with a good prognosis and a strong immune system (T cell) response.
The related research was done in collaboration with researchers from Dartmouth-Hitchcock Norris Cotton Cancer Center and other institutions.
Dr.
Mary Jo Turk led the research.
Dr.
Mary Jo Turk led the research.
(Image source: www.
pixabay.
com)
pixabay.
com)
Turk said: "We are trying to understand how patients who respond well to immunotherapy can resist the immune response of cancer for a long time, aiming to discover the whereabouts, role and duration of T cells in these patients.
Some T cells have a short duration, while others Some so-called memory T cells can last for several years.
In this regard, this work is to understand how these patients produce memory T cells.
"
Some T cells have a short duration, while others Some so-called memory T cells can last for several years.
In this regard, this work is to understand how these patients produce memory T cells.
"
Studies have found that T cells that enter melanoma also tend to enter the skin of patients with vitiligo.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
The results of the study were published in the journal Nature Cancer.
Turk said: "We have found that T cells can persist in the skin and blood for many years, and we understand this long-lasting immune response in melanoma patients.
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer.
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
(Image source: www.
pixabay.
com)
pixabay.
com)
Turk said: "We are trying to understand how patients who respond well to immunotherapy can resist the immune response of cancer for a long time, aiming to discover the whereabouts, role and duration of T cells in these patients.
Some T cells have a short duration, while others Some so-called memory T cells can last for several years.
In this regard, this work is to understand how these patients produce memory T cells.
"
Some T cells have a short duration, while others Some so-called memory T cells can last for several years.
In this regard, this work is to understand how these patients produce memory T cells.
"
Studies have found that T cells that enter melanoma also tend to enter the skin of patients with vitiligo.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
The results of the study were published in the journal Nature Cancer.
Turk said: "We have found that T cells can persist in the skin and blood for many years, and we understand this long-lasting immune response in melanoma patients.
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer.
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
(Image source: www.
pixabay.
com)
pixabay.
com)
Turk said: "We are trying to understand how patients who respond well to immunotherapy can resist the immune response of cancer for a long time, aiming to discover the whereabouts, role and duration of T cells in these patients.
Some T cells have a short duration, while others Some so-called memory T cells can last for several years.
In this regard, this work is to understand how these patients produce memory T cells.
"
Some T cells have a short duration, while others Some so-called memory T cells can last for several years.
In this regard, this work is to understand how these patients produce memory T cells.
"
Studies have found that T cells that enter melanoma also tend to enter the skin of patients with vitiligo.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
The results of the study were published in the journal Nature Cancer.
Turk said: "We have found that T cells can persist in the skin and blood for many years, and we understand this long-lasting immune response in melanoma patients.
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer.
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
Studies have found that T cells that enter melanoma also tend to enter the skin of patients with vitiligo.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
Compared with blood, skin accumulates more tumor-associated T cells; T cells in melanoma tumors are genetically and molecularly similar to those in skin affected by vitiligo.
With these findings, the research team identified a new "Resident Memory" (TRM) cell subpopulation, which is located in the patient's skin and tumors and can produce high levels of the cytokine interferon gamma.
TRM-IFNγ cells have unique gene expression profiles or "features", and are present in large numbers in melanoma tumors of survival time patients.
The authors found that T cells that penetrate the tumor can persist in the skin and blood of patients for up to nine years.
The results of the study were published in the journal Nature Cancer.
Turk said: "We have found that T cells can persist in the skin and blood for many years, and we understand this long-lasting immune response in melanoma patients.
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer.
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
The results of the study were published in the journal Nature Cancer.
Turk said: "We have found that T cells can persist in the skin and blood for many years, and we understand this long-lasting immune response in melanoma patients.
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer.
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
Turk said: "We have found that T cells can persist in the skin and blood for many years, and we understand this long-lasting immune response in melanoma patients.
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
These findings will help better design therapies that achieve this type of response.
"(Bioon.
com)
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer.
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer.
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Information source: com/news/2021-03-cellular-evidence-immune-response-cancer. html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
html">Researchers find cellular evidence behind lasting immune response in some cancer survivors
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
Original source: Han, J.
, Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
Original source: Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. , Zhao, Y.
, Shirai, K.
et al.
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.
Nat Cancer 2, 300–311 (2021).
https ://doi.
org/10.
1038/s43018-021-00180-1
Nat Cancer
